Is platinib currently covered by medical insurance?

Pralsetinib, as an innovative targeted drug, has been approved for marketing in my country, but as of now, it has not been officially included in the national medical insurance directory. This means that patients need to bear all the drug costs themselves when using platinib treatment, which imposes a heavy financial burden. Platinib is mainly suitable for the treatment of patients with non-small cell lung cancer carrying RET gene fusion mutations. It has shown good therapeutic prospects in clinical application and has therefore received widespread attention.

In the domestic market, the original drug Platinib usually comes in two common packaging specifications: 100mg 60 tablets and 100mg 120 tablets. In terms of price, a box of 60 pills usually costs more than 20,000 yuan, while a box of 120 pills may cost more than 60,000 yuan. The specific cost varies depending on the region and channel. The high cost of drugs has also become a major obstacle faced by many patients, making many people look forward to their early inclusion in the medical insurance system to reduce financial pressure.

Compared with domestically, the price of platinib’s original drug in overseas markets is more expensive. Taking a 60-capsule package as an example, the price usually fluctuates between 40,000 to more than 100,000 yuan, depending on the specific country and procurement channel. Due to the extremely high cost, many patients in need are forced to learn about other alternatives in order to find more affordable treatment options.
In order to meet the actual needs of patients, generic drugs of Platinib have been launched overseas. Taking the version produced in Laos as an example, the specification is 120 capsules and the price is about more than 3,000 yuan. It has a clear price advantage compared to the original drug. This type of generic drugs is as close as possible to the original drugs in terms of ingredients and therapeutic effects, providing more choices for some patients with limited economic conditions. However, patients are still advised to carefully screen the source of the drugs and consult professional doctors for guidance before use.
Reference: https://gavreto.com/